Half Year Results 

Shield Therapeutics rebounds

Shield Therapeutics rebounds

When a pharmaceutical company announces unexpected data from a clinical trial, investors tend to panic. Such was the case in early February 2018 when Shield Therapeutics’ (STX) iron deficiency treatment Feraccru produced a surprisingly disappointing result in a final phase US trial. Having sifted through the data and found that the problems were isolated to a handful of patients who had violated the study’s protocol, Shield had gained permission from US regulators to proceed with a new drug application by the end of February. But the damage was done. Shield had lost 84 per cent of its value in one month.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now